Medical Futurist July 7, 2020
1.5 billion: that’s the number, in dollars, Forbes put for Proteus’ valuation last year. Dubbed as a healthcare unicorn, the startup even raised over $500 million in venture capital. It made headlines for developing the first-ever FDA-approved digital pill, one equipped with an ingestible and trackable sensor to monitor treatment compliance.
Researchers even proved the technology’s worth. In 2019, an independent study investigated the Proteus’ digital pill. They found it to be accurate, and even improved adherence of tuberculosis patients using oral pills equipped with Proteus’ system.
How then, did this company file for bankruptcy in June 2020? As the technology is sound, it’s another factor altogether that’s the culprit here: the human factor. The management failed to reach...
Today's Sponsors
Today's Sponsor